REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a pill make CAR T-Cell therapy last longer?
Disease control Recruiting nowThis early-phase trial tests whether the drug pomalidomide can improve the effects of CAR T-cell therapy in people with B-cell leukemias or lymphomas that have returned or not responded to treatment. The study will enroll 12 adults who have already received CAR T-cell therapy. Re…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New cocktail of cancer drugs shows promise for tough lymphoma
Disease control Recruiting nowThis early-stage study is testing a drug called loncastuximab tesirine (ZYNLONTA) combined with other anti-cancer agents in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goal is to find safe doses and see how well the combinat…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called IC19/1563 for people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recogn…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Experimental combo aims to tackle tough lymphomas
Disease control Recruiting nowThis early-phase trial is testing whether combining the immunotherapy drug nivolumab with the drug ASTX727 can help shrink or stabilize B-cell lymphomas that have returned or are not responding to treatment. About 32 adults with certain types of lymphoma will receive the combinat…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New immune cell combo tackles tough lymphoma
Disease control Recruiting nowThis study tests whether a special type of immune cell (ONC-PluReceptor NK cells) given with two antibody drugs (epcoritamab and tafasitamab) can control B-cell Non-Hodgkin lymphoma that has come back or not responded to prior treatments. About 30 adults aged 18-80 who have alrea…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New drug combo aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced or treatment-resistant solid tumors, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 participants will take part in t…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Experimental combo therapy aims to outsmart lymphoma
Disease control Recruiting nowThis early-phase trial tests a new approach for people with intermediate or high-grade B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It combines specially engineered immune cells (CAR T cells) that target cancer cells with a vaccine designed to boo…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Brain training before CAR-T may protect memory, study hopes
Symptom relief Recruiting nowThis study tests an online cognitive training program called I-CAN in 90 adults with relapsed multiple myeloma or B-cell non-Hodgkin lymphoma who are about to receive CAR-T cell therapy. The training aims to reduce the memory, attention, and thinking problems that often follow ca…
Matched conditions: REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:38 UTC